Market Introduction
The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.
Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the South and Central America cardiometabolic diseases market.
Brazil, Argentina, Uruguay, Chile, Peru, Colombia is concerned by the second wave of corona infection. Amongst which Brazil has registered the majority of the deaths. It is anticipated that the region will likely force a second lockdown, which will ultimately hamper the healthcare industry in the area. There have been intensive attempts to explore drug therapy to prevent and treat SARS-CoV-2 infection during this COVID-19 pandemic. Thus, the ongoing clinical studies regarding cardiometabolic diseases market for COVID in the region is likely to favor the growth of the market.
Market Overview and Dynamics
The South and Central America cardiometabolic diseases market is projected to reach US$ 10,295.5 million by 2028 from US$ 8,472.6 million in 2021; it is anticipated to grow at a CAGR of 2.8% from 2021 to 2028. The healthcare industry's transformation from one-size-fits-all to a targeted approach is expanding the demand for personalized medicines. Due to advances in personalized medicine based on individual genetic structure, these medicines are steadily becoming the trademark of chronic disease treatments. The increasing research on the integration of personalized treatment for chronic diseases is opening new therapeutic avenues. Pharmaceutical giants have also been exploring personalized treatment options for CMDs. Recently, Novartis received rights from Akcea Therapeutics to develop and commercialize TQJ230, an investigational agent for targeted cardiovascular therapy. Millions of people have elevated lipoprotein (a), an independent inherited CVD risk factor that cannot be effectively addressed by diet and other lifestyle changes. If approved, TQJ230 could be the first-in-class treatment, explicitly targeting elevated Lp(a). Also, advancements in AI and data analytics are supporting disease management development by personalizing medicines to provide precise intervention. These factors have increased the growth trajectory of the South and Central America cardiometabolic diseases market.
Key Market Segments
In terms of type, the cardiovascular disease segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the South and Central America cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in South and Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bayer AG, Novartis AG, Kowa Company, Ltd., Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, and AstraZeneca.
Reasons to Buy Report
SOUTH AND CENTRAL AMERICA CARDIOMETABOLIC DISEASES MARKET SEGMENTATION
By Type
By Treatment
By Dosage
By Route of Administration
By End Users
By Distribution Channel
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 8,472.6 Million |
| Market Size by 2028 | US$ 10,295.5 Million |
| CAGR (2021 - 2028) | 2.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South and Central America Cardiometabolic Diseases Market is valued at US$ 8,472.6 Million in 2021, it is projected to reach US$ 10,295.5 Million by 2028.
As per our report South and Central America Cardiometabolic Diseases Market, the market size is valued at US$ 8,472.6 Million in 2021, projecting it to reach US$ 10,295.5 Million by 2028. This translates to a CAGR of approximately 2.8% during the forecast period.
The South and Central America Cardiometabolic Diseases Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Cardiometabolic Diseases Market report:
The South and Central America Cardiometabolic Diseases Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Cardiometabolic Diseases Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Cardiometabolic Diseases Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Cardiometabolic Diseases Market
